<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
New fill/finish partnership with BioConnection provides end-to-end drug product development under 1 contract!   Read the press release

2 min read

CGT Manufacturing & Commercialization Europe, December 4-7

CGT Manufacturing & Commercialization Europe, December 4-7

Booth: #216

Date: December 4-7, 2023

Location: Convention Centre Dublin

Event website: https://informaconnect.com/celltherapy/ 

Featured Presentation

Building Flexible End-to-End Cell Therapy Manufacturing Strategies | Tuesday, 5 December 2023 14:50 - 15:20
GMT

Join the General Manager of our Milan Cell and Gene Center of Excellence, Luca Alberici, as he explores:

  • Real-life examples of unit operation optimization
  • Effectively scaling up cell therapy processes
  • How to increase capacity through flexible facility design

MEET OUR TEAM at the show

Would you like to talk with one of our team members? Interested in learning more about our global network and capabilities? Click the button below or email one of our attending representatives at the event to set up a meeting.

REQUEST A MEETING

You can also reach out directly to our experts attending the show

Christoph Winterhalter
Sr. VP, Business Development
Email  me
Luca Alberici
Site Head, Milan Facility
Email  me
Giuliana Vallanti
VP, Development & Global R&D Cell and Gene Therapies
Email  me
Manuel Balbuena
Director, Business Development
Email  me

Explore our new AAV & LVV Platforms

BravoAAV™ and ProntoLVV™ are end-to-end platforms offering a proprietary GOI backbone and plug-and-play templates for any project. Our services include proprietary plasmids, in-house analytical panels, master cell banks, pre-qualified processes and fill and finish services.  

Our new templated adeno-associated viral vector platform.

 Learn about Bravo

Our new templated lentiviral vector platform.
 

Learn about our cell and gene therapy services 

Cell Therapy Production and Manufacturing

AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.  

Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting. 

Learn more about our overall cell therapy offering 

 

Plasmid DNA (pDNA) Materials 

To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing. 

Learn more about our Plasmid offering

 

Viral Vector Production and Manufacturing 

AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products. 

Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house. 

Discover more about our viral vector services 

 

Fill out the form below to request a meeting during the event